Ribbon: A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer
Ribbon: A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer
Project number : 246021
Created by: Ylva Storck, 2018-03-26
Last revised by: Ylva Storck, 2018-03-26
Project created in: FoU Region Örebro län

CompletedCompleted
2006-11-21
Rekrytering/datainsamling pågår
2009-12-31
Projektet avslutat

Registeranmälan

  1. Ribbon: A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer, PUL-anmälan
  2. Ribbon: A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer, Projektbeskrivning

Titel och sammanfattning

Populärvetenskaplig sammanfattning

Studien vänder sig till patienter med spridd bröstcancer där man , utöver cytostatika, prövar tillägg med bevacizumab. De flesta av patienterna kommer att få bevacizumab medan övriga får placebo

Projektspecifik information

Ämnesord

checked Cancer och onkologi


(Only selected options are displayed. Click here to display all options)

Studietyp

Prövning av läkemedel

Fas

III

Randomiserad studie

Ja

Diagnoskod för huvuddiagnos

C50-C50 Malign tumör i bröstkörtel

Multicenterstudie

Ja

Protokollnummer på prövningen

AVF3694g

Etikprövningsmyndighetens diarienummer

2006/164

Biobanksavtal

Ej aktuellt

Inklusionsstatus

 Planerat antalAntal tillfrågadeScreen-failureAntal randominserade
n= 4 screenade 2

Vetenskaplig sammanfattning

The primary endpoint is PFS, defined as the time from randomization to first disease progression or any cause of death, whichever occurs first. Investigator assessments based on RECIST will be used to determine progression

Involverade parter

Arbetsplats

Added workplaces

Regioner - Region Örebro Län - Hälso- och sjukvård - Område opererande och onkologi - Onkologiska kliniken workplace verified by Region Örebro län on 2018-06-14

Sponsor

Added workplaces

Miscellaneous
(Pick this work place if you can't find your workplace)

Nationell koordinator

Added workplaces

Regioner - Region Uppsala - Akademiska sjukhuset - Blod- och tumörsjukdomar

Ribbon: A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer, from FoU Region Örebro län
http://www.researchweb.org/is/en/fourol/project/246021